2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Key Result

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are key pharmacological therapies updated in the 2016 ACC/AHA/HFSA guidelines for the management of heart failure.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

◼ angioedema ◼ angiotensin-converting enzyme inhibitors ◼ angiotensin receptor blockers ◼ angiotensin receptor

Read Full Paperexternally

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Yancy et al. (Mon,) reported a other. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are key pharmacological therapies updated in the 2016 ACC/AHA/HFSA guidelines for the management of heart failure.

synapsesocial.com/papers/6a0bd79cdc69176b05a940c0 https://doi.org/https://doi.org/10.1161/cir.0000000000000435